News & Views

Telix is in Los Angeles this week for the SNMMI 2026 Annual Meeting. This year’s program features seven abstracts from across Telix’s oncology portfolio, including three oral presentations exploring novel imaging approaches in clear cell renal cell carcinoma, thyroid cancer and bone marrow dosimetry.

Telix advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will participate in the upcoming William Blair 46th Annual Growth Stock Conference in Chicago, IL and in the Jefferies Global Healthcare Conference in New York, NY.

Courtney Watson is the Director of Programs and Communications at Head for the Cure, a nonprofit organization dedicated to raising awareness and funding for the brain tumor community. Her mother, Sandra was diagnosed with glioblastoma (GBM) in 2016 and passed away the same year — less than nine months after diagnosis. We spoke to Courtney about her family’s journey, the challenges of navigating a GBM diagnosis, and the work she does every day to make sure no one faces this disease alone.

Telix today announces that the IPAX-2 study[1] of TLX101-Tx (¹³¹I-iodofalan) in patients with newly diagnosed glioblastoma has completed patient enrolment. No dose-limiting toxicities (DLTs) have been observed to date, including with two doses of 5GBq (total administered activity of 10GBq), the maximum administered dose in the study.

Telix today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A.(NASDAQ: EDAP, “EDAP”) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN, “Profound”), leading companies developing advanced minimally invasive and image-guided treatment ablative technologies for prostate cancer, including focal, subtotal, and whole-gland treatment approaches. These initiatives reflect Telix’s commitment to advancing the integration of molecular imaging into the evolving prostate cancer treatment landscape to help inform clinical decision-making.

Telix today announces the publication of a new independent analysis of Phase 3 ZIRCON trial data in European Urology, demonstrating that TLX250‑Px (Zircaix®, 89Zr-girentuximab) PET/CT imaging may be highly predictive of renal malignancy across all subtypes, not limited to clear cell renal cell carcinoma (ccRCC).

Telix today announces that the marketing authorization application (MAA) filed in Europe for TLX101-Px (O-(2-[18F]fluoroethyl)-L-tyrosine, 18F-FET), its glioma (brain cancer) imaging candidate, has been validated and accepted for review.

Telix today announces dosimetry results from the randomized Phase 2 OPTIMAL-PSMA trial of TLX597-Tx in metastatic castration-resistant prostate cancer (mCRPC), presented at the 2026 International Prostate Cancer Symposium (IPCS 2026) held in Lugano, Switzerland. These findings support TLX597-Tx’s potential to deliver a treatment that overcomes quality-of-life challenges that currently limit the clinical utility of existing RLTs in earlier-stage metastatic prostate cancer.

Telix announces an investor webinar exploring the evolution of PSMA-targeted radionuclide therapy and Telix’s differentiated, multi-product approach to treating prostate cancer across the disease continuum.

Telix today announces that safety and tolerability data from the ProstACT Global Phase 3 study (Part 1) will be presented as a late-breaking oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago, IL.